Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer: HCCSC G05 Trial
Latest Information Update: 02 Nov 2021
At a glance
- Drugs Camrelizumab (Primary) ; Docetaxel (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Rivoceranib (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms HCCSC G05
- 22 Mar 2021 Drug changed from Carrizumab to Camrelizumab.
- 22 Mar 2021 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Mar 2021 to 1 Apr 2021.
- 09 Mar 2021 New trial record